Headlines

Pfizer heralds “paradigm shift” in hemophilia B gene therapy with FDA approval

Pfizer's groundbreaking $3.5 million gene therapy for Hemophilia B just got FDA approval. Here’s what it means for patients and the future of medicine

Why are nearly half of all recent biotech alliances in Asia-Pacific betting big on RNA therapies?

A recent study finds RNA deals are “dominated” by oligonucleotides and mRNA vaccines in APAC

Tolerizing vaccines for autoimmune diseases tempt BMS into $1.8bn collaboration

Bristol Myers Squibb partners with Repertoire Immune Medicines to develop innovative vaccines aimed at treating autoimmune disorders more selectively and effectively

SynOx takes rare tumour treatment to phase 3 with $75m Series B

Could SynOx's $75M Phase 3 Trial Be the Next Big Leap in TGCT Treatment?

Bristol Myers Squibb enlists Cellares amid industry manufacturing “land grab”

With equipment that promises to produce 10 times more therapies, the deal with Cellares is hoped to make BSM's CAR-T ambitions more scalable and affordable

AstraZeneca’s Lynparza to remain dominant in PARP inhibitors market with $4 billion in sales by 2027

Back in 2014, AstraZeneca and Merck were the first to receive FDA approval for their PARP inhibitor Lynparza (olaparib) for use in breast cancer gene (BRCA)-mutated metastatic ovarian cancer patients.